By Gareth MacDonald

Biosimilars will mean more facility inspections and reviews according to the US FDA, which is confident its funding will be increased accordingly.

Read more at http://www.biopharma-reporter.com/Markets-Regulations/US-FDA-expects-more-resources-to-fund-biosimilar-reviews-and-plant-inspections